Introduction
Tuberous sclerosis complex (TSC) is a rare genetic disease caused by a mutation in the TSC1 or TSC2 genes, coding for the proteins hamartin and tuberin, respectively [1] . TSC1 and TSC2 form an inhibitory complex with GTPase-activating protein (GAP) activity. This keeps Ras homolog enriched in brain (Rheb) bound to GDP and in an inactive form, preventing downstream phosphorylation of mechanistic target of rapamycin (mTOR). In humans and animal models of TSC, mutations in TSC1 or TSC2 impair the inhibitory function of the complex, allowing activation of Rheb by GTP and constitutive activation of mTOR [2, 3] .
mTOR is a major convergence point for extracellular signalling, through regulation of anabolic processes such as transcription and translation [4] . This regulation of protein synthesis by mTOR extends throughout the mammalian lifespan and is crucial for central nervous system (CNS) development, where it controls soma size, dendritic arborisation, cortical lamination, and plasticity [5, 6] .
Overactivation of mTOR is evident in the majority of TSC patients that present with benign tumours in several organs, such as skin, kidneys and brain [6, 7] . These often require surgical treatment and are a major source of morbidity for patients [8] . Furthermore, disruption of mTOR function in TSC also leads to neurological and neuropsychiatric complications in 85% of patients. Brain lesions such as cortical dysplasia, subependymal nodules and tubers are present in 70-90% of these patients [1] . Importantly, tubers and the perituberal tissue have long been associated with epilepsy, the most common neurological manifestation in TSC. In fact, 80-96% of patients have epilepsy with two thirds refractory to existent therapies [1, 9] . Failure to control seizures in TSC patients is highly correlated with an early onset of seizures, before the age of 1 year old, in the form of focal epilepsy and infantile spasms [10] . Epilepsy is frequently associated with tuberous sclerosis associated neuropsychiatric disorders (TAND), such as autism spectrum disorder, present in 40-50% of patients, and intellectual disability, present in 30% [9, 11] . The importance of seizure control is further reinforced by its positive impact on developmental outcomes and quality of life assessments [12, 13] . Nonetheless, despite the availability of some treatment options, due to the high heterogeneity of manifestations and TSC phenotype, not all individuals respond to the currently available therapies and new options are needed to attend to the patients' needs [10, 14, 15] .
Given that a vast array of different systems and organs are affected by TSC, treatment typically requires a poly-pharmacological approach. mTOR inhibitors, such as rapamycin and everolimus, are current firstline treatments to control the growth of asymptomatic lesions. Epilepsy treatment can include one or multiple anti-epileptic drugs (AEDs), especially if resistance is present. Vigabatrin, which has been proposed to modulate both GABA levels and the mTOR pathway [16] , displays good efficacy in TSC and is the most commonly used AED in these patients [9, 17] . Regarding TAND, no specific therapies are yet approved, although early-intervention neuropsychiatric programmes, seizure control and mTOR inhibition have shown to contribute to cognitive improvement [9, 18] .
There is growing evidence to support the use of cannabidiol (CBD), the most abundant non-euphoric phytocannabinoid derived from Cannabis sativa [19] , in the management of seizures [20] . Previous in vitro and in vivo studies have demonstrated the efficacy of CBD in reducing the frequency and severity of seizures, in different models of epilepsy [21, 22] . More recently, two clinical trials provided evidence of a CBD induced reduction in the median frequency of convulsive seizures and of drop seizures, in Dravet Syndrome (DS) and LennoxGastaut Syndrome, respectively [23, 24] . Additionally, an expandedaccess study of CBD for patients with TSC also suggested an effect of CBD in reducing seizure frequency in this population [25] . CBD has also shown beneficial effects in tumour studies. in vitro reduction of cellular viability and proliferation was demonstrated in both tumour cell lines [26] [27] [28] [29] [30] [31] and primary tumour cells [26] , whilst reducing tumour volume [26, 28, 31] and metastasis in vivo [31] [32] [33] . Importantly, CBD has been shown to modulate some components of the mTOR pathway [30, 31, [34] [35] [36] [37] [38] , however there is a divergence in the reported effects with evidence from the cancer field supporting a CBD inhibition of mTOR, while epilepsy studies indicate an activation of mTOR. Therefore, in the complex pathology of TSC, the modulation of mTOR signalling via CBD is unclear.
Several animal models are available for the study of TSC, although none of these fully replicates all features of the human disease [39] . Mammalian models include the Eker rat, with a spontaneous Tsc2 mutation, and several conditional knockout mice which allow biallelic inactivation of Tsc1 or Tsc2 in a cell specific manner [39, 40] . Nonmammalian models are also widely used, as it is the case of Saccharomyces cerevisiae, Drosophila and zebrafish [41] . The zebrafish model of TSC used here carries the nonsense vu242 mutation in the tsc2 gene [42] . This renders tuberin inactive as it lacks the functional GAP domain. Several human-like disease features, such as increased phosphorylation of rpS6, a protein downstream of mTOR and often used as a readout of mTORC1's activity [43, 44] , increased cell size and early death of homozygotes, are present in this model [42] . More recently, an mTOR-dependent disruption of locomotor behaviour was also demonstrated in homozygous tcs2 −/− larvae [45] . Here we use a zebrafish model of TSC to examine the effects of CBD on the pathogenesis of TSC, including behavioural effects and ribosomal protein 6 phosphorylation. Our data highlights that CBD can modulate the mTOR pathway, through regulating the phosphorylation status of ribosomal protein 6 in a relevant model of TSC. 
Materials and methods

Zebrafish husbandry
Maximum Tolerated Concentration (MTC)
6 dpf larvae were placed in a 24 well-plate (Corning Inc., New York, USA) and incubated with 396 μL of swimming medium (Danieau's) and 4 μL DMSO (0.1 or 1%) or CBD (GW Pharmaceuticals, Cambridge, UK) dissolved in DMSO. CBD was serial diluted and tested in concentrations ranging from 0.3 μM to 125 μM. Plates were then transferred to a 37°C incubator, in the dark, and larvae touch-response was tested after 1 and 24 h of incubation. The MTC was defined as the highest concentration of CBD in DMSO that did not induce any observable signs of toxicity, such as necrosis, abnormal heart beat or loss of posture [46] .
Locomotor assay
The locomotor assay was performed as previously published [45] . In brief, 6 dpf larvae were placed in a 24 well-plate, treated with Danieau's (called naïve larvae in the text), 0.1% DMSO or 1.25 μM CBD in 0.1% DMSO, and incubated in dark for 24 h. Plates were then removed from the incubator and placed in a Zebrabox, where movement of the larvae was automatically tracked and expressed in "actinteg" units (which is the sum of pixel changes detected during tracking). Here, fish were habituated for 10 min under both light and dark condition before being tracked for 5 min in both the light and dark conditions. To measure anxiogenic or anxiolytic effects due to compound administration, changes in the startle response upon light to dark transition were measured as previously published [47, 48] . Touch response (TR) can be used to corroborate the MTC data as it is also a measure of larval peripheral reflexes [49] . Touch-response was tested, by touching the larvae's tail with a blunt needle, before and after tracking to monitor toxicity. The number of responding and non-responding larvae was registered. All researchers were blinded to genotype throughout behavioural testing and data analyses.
Chronic treatment and survivability assay
Larvae were cultured in 200 μl of Danieau's, in a 96-well plate, and followed from 3 dpf until 10 dpf. Medium was changed every other day and 0.1% DMSO or 1.25 μM CBD in 0.1% DMSO added to the wells. The number of dead larvae was counted daily. At the end of the assay, the surviving larvae underwent the previously described locomotor assay.
Genotyping
Genotyping was conducted as previously published [45] . In summary, after sacrifice, zebrafish tails were collected and lysed for 3 h, at 55°C, followed by 10 min at 95°C. PCR was performed on the lysates using Pfu polymerase (Thermo Scientific, UK), and the primers GTAA CACAGAATCAGTGAATCGGA (forward primer) and CACACACAGAAA ACACTTGAAGC (reverse primer). After PCR, samples underwent digestion with HpyCh4 IV (New England Biolabs, UK), for 1 h, at 37°C, followed by fragment separation on a 2% agarose/ 0.5 μg/mL ethidium bromide gel, for 1 h, at 110 V. Due to post-mortem genotyping, and because a smaller ratio of tsc2 −/− larvae is obtained compared to tsc2 +/+ and tsc2 +/-, variation in group sizes exists throughout experiments.
Immunohistochemistry (IHC)
After completion of the locomotor assay, 7 dpf zebrafish larvae were sacrificed in ice cold water. Heads were dissected and placed in 4% PFA for 48 h, at 4°C, and then transferred into a 30% sucrose in PBS solution, at 4°C. These were then embedded in optimum cutting temperature (OCT) compound and stored at -80°C until sectioned. 10 μm sections were cut and collected onto microscope slides (SuperFrost Plus, Thermo Fisher Scientic, UK) and stored at -80°C until used.
For IHC, sections were incubated for 2 h, at room temperature, in a 2% BSA, 10% horse serum and 0.05% TX-100 buffer, followed by an overnight incubation with a primary antibody against phosphorylated rpS6 (Ser235/236) (1:500; 2211 New England Biolabs, lot 0023, UK), in a 1% BSA and 0.05% TX-100 buffer, at 4°C. The next day, slides were rinsed in Tris-buffered saline (TBS) and incubated for 2 h, at room temperature, with a goat anti-rabbit Alexa Fluor-647 secondary antibody (1:1000; A-21245 Thermo Fisher Scientific, lot 1805235, UK). After further rinses, sections were counterstained with DAPI (1:10 000; D1306 Thermo Fisher Scientific, UK) for 10 min, rinsed, dried, and mounted. For TUNEL staining (1:10; 12156792910 Roche, lot 26320800, Sigma, UK), slides underwent the same buffer incubation procedure, excluding antibody incubation. After the final rinsing step, sections were incubated with TUNEL solution, in the dark, for 1 h, at 37°C. Negative control was done by omitting the enzyme solution, while positive control was performed by previous incubation of sections with 5 mg/mL DNAse, for 10 min, at 37°C.
Imaging and image quantification
Non-consecutive brain sections were imaged using a Zeiss AxioImager microscope. Exposure time was constant during image acquisition and background fluorescence was measured where the primary antibody or enzyme solution was omitted. Pictures were taken with a 20x objective using the AxioVision software. Original images were processed on Fiji Image J [50] , and a region of interest (ROI) was freehand defined around the brain outline. The average intensity value for each ROI, in each picture, was measured as Intensity Arbitrary Units (IAU), following background subtraction for each picture. For cell counting, cells were considered positive if staining for both phosphorylated rpS6 and DAPI were clearly present. To measure cell size, a similar procedure was used, except five cells per picture were randomly selected and its cross-sectional area measured. A minimum of three animals per group and genotype were used, and 3-9 sections per animal were imaged and counted.
Statistical analysis
Statistical analysis was performed in SPSS (IBM SPSS Statistics 22) and GraphPad Prism 5. Repeated measures two-way ANOVA was used to analyse data from the locomotor assay (genotype x treatment x exposure to light/dark) and phosphorylated rpS6 positive cell number (genotype x treatment x number positive cells/section), while a threeway ANOVA was used to analyse cell size (genotype x treatment x area of cells). Touch response (TR) (yes x no) was analysed by chi-square test and TUNEL positive cells with the Kruskal-Wallis test. Normality was assessed with the D'Agostino-Pearson omnibus test. Statistical testing was followed by Tukey or Bonferroni post-hoc tests.
Data are expressed as mean ± SEM unless stated otherwise, and significant values were considered when p ≤ 0.05. All graphs were prepared with GraphPad Prism 5.
Results
CBD safety profile
To determine the maximum tolerated concentration (MTC) to be used in further experiments, CBD and DMSO were tested at different concentrations, ranging from 0.3 μM to 125 μM CBD in DMSO, and 0.1% to 1% respectively.
Concentrations from 5 to 125 μM CBD in 1% DMSO, induced varying levels of toxicity in the larvae, manifested by slow heartbeat, loss of posture and death. We then compared lower CBD concentrations (0.3 to 2.5 μM) in 0.1 or 1% DMSO. Here, the toxicity of CBD was reduced with the decrease in DMSO concentration from 1% to 0.1%. 1.25 μM CBD in 0.1% DMSO was the highest CBD concentration in which all animals were alive after 24 h and showed no signs of gross morphological abnormalities.
At a cellular level, toxicity signs were absent from the central nervous system, as indicated by a non-significant difference (p = 1.0) in the number of apoptotic cells, as indicated by positive TUNEL staining (Fig. 1A-C) .
Regarding touch-response, compared to both the Danieau's and 0.1% DMSO treated groups, administration of CBD from 6 to 7 dpf did not affect the percentage of responders to touch (χ 2 (2) = 2.51, p = 0.3; 98.0% for Danieau's, n = 155; 95.8% for 0.1% DMSO, n = 166; 94.7% for CBD, n = 171), as manifested by a non-significant difference in the TR of treated larvae (Fig. 2A). 
Behavioural effects of CBD
CBD does not induce sedation in this zebrafish TSC model
Next, we analysed larvae locomotor behaviour. To test the reported sedative properties of CBD [23, 25] , we quantified the average swimming movement of larvae during the light period, as a reduction of overall exploratory movement can be used as a measure of sedation [51, 52] . There were no statistically significant differences in the baseline behavioural exploration, between vehicle (0.1% DMSO, 24 h incubation) and CBD (1.25 μM, 24 h incubation) treated larvae (F (1,322) (Fig. 2B) .
CBD reduces startle response of zebrafish larvae during the dark period
Zebrafish larvae respond to changes in light beginning from 5 dpf [53, 54] , and sudden changes from light to dark induce a startle response. Decreased locomotion after a startle stimulus is indicative of an anxiolytic effect [52, 53, [55] [56] [57] . Here, CBD (1.25 μM, 24 h incubation) treatment significantly reduced dark-induced movement compared to (Fig. 2C) .
CBD does not rescue homozygote behavioural phenotype
One of the features of this model is early death of tsc2 −/− homozygotes, between 9 and 11 dpf [42, 45] . This can also be seen in other TSC model organisms, such as mice and rats, which typically die at embryonic day 10-10.5 [58] [59] [60] . Additionally, reduced overall locomotion was recently shown in tsc2 −/− larvae [45] . We therefore assessed the effects of long-term CBD incubation, from 3 to 10 dpf, on survivability and locomotion. No difference in the survival of tsc2
(1) = 0.27, p = 0.6; n = 72 per group) (Fig. 3A) nor swimming ability (t(1) = 3.06, p = 0.2; 1459.8 ± 366.8 actinteg units, n = 28, vs 2875.6 ± 520.1 actinteg units, n = 27) (Fig. 3B) was found between 0.1% DMSO and CBD treated groups.
CBD modulates phosphorylated rpS6
CBD reduces the number of phosphorylated rpS6 positive cells in tsc2 +/+ , tsc2 +/− and tsc2 -/-larvae
We subsequently assessed the impact of CBD treatment upon rpS6 phosphorylation, which is increased in tsc2 −/− zebrafish [42, 45] groups, confirming what others had previously shown [42, 45] . Unexpectedly, an overall increase in phosphorylated rpS6 intensity was also observed in sections from 0.1% DMSO incubated larvae (10.72 ± 1.7, for tsc2 +/+ , 6.0 ± 0.6, for tsc2 +/-, 12.1 ± 1.4 IAU, for tsc2 −/− ), while reduced immunofluorescence was found in the CBD groups (4.5 ± 0.6, for tsc2 +/+ , 6.0 ± 0.9, for tsc2 +/-, 11.09 ± 1.2, for tsc2 −/− IAU) (Fig. 4A ).
Section size was accounted for by prior analysis of total brain section size. This revealed no significant differences between genotypes or treatments (Fig. 1D) .
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+/+ , tsc2 +/− and tsc2 -/-larvae, respectively) (Fig. 4C) .
Taken together, this data suggests that CBD led to a reduction of phosphorylated rpS6 immunoreactivity in larval brain.
CBD reduces the size of phosphorylated rpS6 positive cells in tsc2 +/ + , tsc2 +/− and tsc2 -/-larvae
The phosphorylation status of rpS6 has been correlated with cell size [37, 61] , therefore we measured the cross-sectional area of phosphorylated rpS6 positive cells in the brain (Fig. 4B) .
A genotype dependent increase in cell area was seen in the naïve group. That is, cells from tsc2 +/− sections were larger than tsc2 , n = 133; p < 0.001) (Fig. 4D) . Therefore, while a difference in the number of phosphorylated rpS6 positive cells between the naïve tsc2 +/+ and tsc2 +/− larvae was absent, here, the area of cells from heterozygote and wild-type animals did differ. Regarding CBD incubated larvae, these had smaller phosphorylated rpS6 positive cells than the ones present in the 0.1% DMSO group (Fig. 4C ). This effect was seen across tsc2 +/+ (22.8 ± 0.7 μm (Fig. 4D ). Similar to results seen for cell number, where an effect of 0.1% DMSO was reported, a DMSO-driven increase in cell size was also observed here (Fig. 4D ). This was also significantly supressed by CBD incubation. Altogether, these data indicate that CBD reduces genotype and DMSO-induced increase of size in tsc2 +/− and tsc2 -/-zebrafish brain cells.
Discussion
CBD is a non-psychoactive component of Cannabis, that has increasingly been recognised as the basis for pharmacology intervention in a host of diseases [19, 20, 62] . Here we examine the effects of CBD to modulate aberrant mTORC1 signalling in zebrafish carrying a tsc2 mutation.
Anxiety is a TSC-associated neuropsychiatric disorder and evidence indicates altered serotonin signalling as a biological mechanism [65] [66] [67] [68] . One of the proposed targets for CBD is the 5-HT 1A receptor, where it has been shown to bind and to have agonist functions at concentrations ≥10 μM in vitro [73, 74] . Several serotonin receptors, orthologues to human receptors, have been shown to be expressed in zebrafish larvae, including the 5-HT 1A receptor [72, 79] . This is pertinent to the current study with the 5-HT 1A receptor a proposed site of action for CBD [73, 74] . However, contrasting with the function of mammalian 5-HT 1A receptors, the role of these receptors on anxiety behaviour in zebrafish is less defined. For example, extracellular serotonin content has been reported to have contrasting effects on anxiety in the same adult zebrafish species [72, 80] . Larvae, in contrast to their adult counterparts, exhibit a transient elevation in motor activity in response to sudden onset of darkness [53, 64, 81] . Dark avoidance was shown to be modulated by anxiolytic drugs such as the 5-HT 1A agonist, buspirone, which increased dark preference patterns in zebrafish larvae [81] .
Here we demonstrate a CBD induced reduction in startle response across genotypes However, a limitation of this model is that tsc2 −/− larvae do not reach adulthood and, therefore, later behavioural testing cannot be performed to confirm an anxiolytic effect of CBD in this genotype. Nonetheless, further studies in tsc2 +/-larvae could still be beneficial to elucidate possible effects of CBD in TSC, given the clinical TSC population are heterozygous [7] . Several molecular processes have been proposed to modulate CBD actions [19] . The serotonergic system is one such example and modulation here could provide control of other TSC features such as epilepsy, highly prevalent in TSC patients [17] . Evidence from epilepsy studies indicates that a reduction in serotonin concentration promotes seizures, while reduced serotonin binding to the 5-HT 1A receptor has been reported in epileptogenic foci [83, 84] . Studies also indicate that TSC patients present with increased tryptophan uptake localised to epileptic foci [85] . Given that CBD has been shown to reduce seizures in pathologies with different aetiologies [23, 25, 89] , and that tsc2 −/− zebrafish, and other TSC models, have been shown to exhibit abnormal brain activity [45, [90] [91] [92] , it would be relevant to further study its role in the serotonergic system of TSC models.
A hallmark of TSC across all experimental models is an increase in mTOR activity [1, 3, 5, 6, 42, 45] . Activation of mTOR leads to an increase in the ratio of downstream targets phosphorylated rpS6 /total rpS6, both in in vitro and in vivo models [88, 91, 95, 96] . Therefore, phosphorylated rpS6 is often used as a read out of mTOR activation [97] [98] [99] . The reduction of rpS6 phosphorylation presented here is in line with published work where CBD treatment was found to modulate the mTOR pathway. In breast cancer cells, incubation with CBD has been observed to modulate Akt, a kinase upstream of mTOR, as well as 4E-BP1 and cyclin D [30, 31] . Another study also reported the reduction of ERK phosphorylation, a kinase upstream of mTOR [31] . The effects observed here with 0.1% DMSO may indicate a proinflammatory response [101] [102] [103] with subsequent activation on mTOR [104, 105] .
The mTOR-S6K-S6 axis is also known to have a major role in controlling cell size [98, 106] . In fact, we saw that Danieau's incubated animals showed a mutation-dependent increase in cell size, with tsc2 −/ − brain cells bigger than tsc2 +/− , followed by tsc2 +/+ . These results are similar to previous work on this model, where a difference in size was found between tsc2 +/+ and tsc2 −/− , in liver, brain, and spinal cord cells [42] . In accordance with a reduction in phosphorylated rpS6 positive cells there was a corresponding CBD effect on the cross-sectional area of brain cells. A comprehensive analysis of mTOR activity in phosphorylated rpS6 cells through enzymatic assay would definitely link the disruption in phosphorylated rpS6 to mTOR activity which remains unresolved in this current study. However, contrasting effects on the mTOR signalling pathway by CBD have also been reported. For example, in amphetamine-sensitized rats, CBD reduced levels of pGSK-3β and pAkt, but importantly it induced an increase of pmTOR and pS6K [35] . To further demonstrate the effect of CBD on mTOR specifically, this effect was reversed with the mTOR inhibitor, Torin 2 [35] . Additionally, administration of 10 mg/kg CBD to a mouse model of multiple sclerosis revealed increased pPI3K, pAkt, pmTOR and pS6K in spinal cord tissue. Importantly, in this model, basal levels of mTOR pathway activation were shown to be decreased [36] . Regarding the zebrafish model used here, we observed a decrease in phosphorylated rpS6, which could result from a reduction in mTOR activation. However, the survival and locomotion data regarding the chronically CBD-treated tsc2 −/− larvae highlight that this modulation of mTOR was insufficient to impact these whole system outputs.
Conclusion
In the current study, using a TSC zebrafish model, we demonstrate that CBD was tolerable, while behavioural testing showed that CBD exhibited an anxiolytic profile without sedative effects. Additionally, we showed modulation of rpS6 manifested by the reduction of the number and size of phosphorylated rpS6 positive cells in the brain.
Altogether, these data demonstrate that CBD modulates aberrant mTOR signalling in a model of TSC. It provides a rationale for further investigation into CBD as a therapeutic agent in diseases where mTOR signalling is disrupted.
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